Supplemental Table I. Characteristics of KTR included in the retrospective study

	All patients (n=253)	**CMV symp. infection[a] (n=47)**	**No CMV symp. infection (n=206)**	**p**
Recipient age (years, mean ±SD)	53.8 ± 13.3	60.3 ±10.5	52.3 ±13.4	**<0.001**
Female recipient (n, %)	99 (39.1)	20 (42.5)	79 (39.3)	0.59
Donor age (years, mean ±SD)	51.8 ± 14.1	58.7±10.2	50.2±14.4	**<0.001**
Deceased donor (n, %)	221 (87.3)	41 (87.2)	180 (87.3)	0.97
Female donor (n, %)	107 (42.3)	20 (42.5)	87 (42.2)	0.96
Retransplantation (n, %)	41 (16.2)	6 (12.7)	35 (16.9)	0.47
Pre-KT CMV serostatus (n, %) **-High risk (D+/R-)** **-Intermediate risk (D+/R+, D-/R+)** **-Low risk (D-/R-)**	 4 (1.6) 218 (86.2) 31 (12.2)	 0 38 (80.8) 9 (19.2)	 4 (1.9) 180 (87.5) 22 (10.6)	 0.122 *
Thymoglobulin induction (n, %)	38 (15)	11 (23.4)	27 (13.1)	0.075
Cold ischemia time (hours) median (IQR)	13.8 (10-18)	13.7 (10-17.2)	14 (10-18)	0.98
Pre-transplant PRA CDC>5% (n, %)	13 (5.1)	0	13 (6.3)	0.08
Pre-transplant DSA (n, %)	27 (10.7)	2 (4.2)	25 (12.1)	0.11
Delayed graft function (n, %)	90 (35.6)	20 (42.5)	70 (33.9)	0.94
Biopsy-proven acute rejection (n, %)	15 (5.9)	2 (4.2)	13 (6.3)	0.59
CMV infection time (days) median (IQR)	NA	57 (45-114)	NA	
Follow up time (months) median (IQR)	54 (39-76)	45 (31.5-77.5)	58.6 (41-76)	0.08

[a] *Symptomatic CMV infection with confirmed viremia (see Methods)*

***Abbreviations SD**: Standard deviation. D: donor. R: recipient. IQR: Interquartilic range. PRA: Panel reactive antibodies. CDC: complement derived cytotoxicity. DSA: donor specific HLA antibodies. KT: Kidney transplantation. NA: not applicable.*High vs. intermediate risk comparison*

Downloaded from http://journals.aai.org/jimmunol/article-supplement/105999/pdf/ji_1601236_supplemental_table_1/ by guest on 18 July 2024